Initial Experience of Monitoring Response of Breast Cancer to Bevacizumab-containing Chemotherapy using A New Integrin Specific PET Imaging Tracer [F-18]RGD-K5

Abstract

This study investigates the use of [F-18]RGD-K5, an integrin αvβ3 targeting PET tracer, in breast cancer patients receiving chemotherapy with bevacizumab (Avastin ® ). Two patients were analyzed: Subject-1 had metastatic breast cancers and Subject-2 had a primary cancer in the breast. The therapy regimen was weekly paclitaxel and carboplatin combined with bi-weekly bevacizumab. Each subject received 5 PET-CT scans: pre-treatment [F-18]